Abstract
A 25-year-old woman with AIDS was submitted to HLA-identical allogeneic BMT after cytoablation with busulphan and cyclophosphamide and combined anti-HIV-1 therapy with zidovudine, IFN-alpha 2 and anti-HIV-1-specific T cell clones. Marrow engraftment occurred after 18 days and tests for HIV-1 were negative after 30 days but the hematologic reconstitution of the patient was poor. A second BM infusion from the same donor was ineffective and treatment with GM-CSF only induced a transient increase of the blood cell count, suggesting iatrogenic damage to the BM microenvironment. The development of ARDS led to the death of the patient 10 months after transplantation. Post-mortem investigation did not reveal any active infections and PCR on autopsy tissues was negative for HIV-1.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / immunology
-
Acquired Immunodeficiency Syndrome / surgery*
-
Acquired Immunodeficiency Syndrome / therapy
-
Adult
-
Antilymphocyte Serum / administration & dosage
-
Bone Marrow Transplantation* / adverse effects
-
Bone Marrow Transplantation* / immunology
-
Bone Marrow Transplantation* / methods
-
Busulfan / administration & dosage
-
Combined Modality Therapy
-
Cyclophosphamide / administration & dosage
-
Drug Therapy, Combination
-
Female
-
Graft vs Host Disease / immunology
-
Granulocyte-Macrophage Colony-Stimulating Factor / administration & dosage
-
HIV-1* / isolation & purification
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Recombinant Proteins
-
Respiratory Distress Syndrome / etiology
-
Transplantation, Homologous
-
Zidovudine / administration & dosage
Substances
-
Antilymphocyte Serum
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Zidovudine
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
Cyclophosphamide
-
Busulfan